Drug Interactions Corner

Back to articles

Statins and clarithromycin: Role of non-CYP3A4 interactions

KEY POINT

Results of a large population-based cohort study suggest that there may be a drug–drug interaction between clarithromycin, a potent cytochrome P450 3A4 (CYP3A4) inhibitor, and statins not metabolized by this enzyme (i.e., rosuvastatin [Crestor—AstraZeneca], pravastatin, fluvastatin), which may result in an increased frequency of serious adverse events.